Diasonics will use the RSNA meeting to introduce the latest memberof its Gateway scanner family, Gateway fx. The system makes useof a new expanded-aperture beamformer that combines the best ofanalog and digital beamformers, according to Ken Marich,
Diasonics will use the RSNA meeting to introduce the latest memberof its Gateway scanner family, Gateway fx. The system makes useof a new expanded-aperture beamformer that combines the best ofanalog and digital beamformers, according to Ken Marich, directorof marketing communications for the Santa Clara, CA, vendor.
The new beamformer produces very high dynamic range, betterimage quality, and increased Doppler sensitivity, Marich said.The new beamformer also enables the scanner to extend the focusof Diasonics' 2-D transducers into the deep abdomen. In addition,Gateway fx features a larger 12-inch dual monitor.
Gateway fx has 510(k) clearance, and Diasonics plans to beginshipments shortly after the RSNA show, with the scanner sellingfor $150,000 to $200,000.
Other new features to be shown in the Diasonics exhibit includeOB Advisory, an ob package that enhances the ability to determinethe gestational age of a fetus; SmartCaliper for the automatedplacement of measurement calipers; and OB Trend Analysis, whichenables clinicians to track six key fetal growth factors.
In the networking arena, Diasonics has expanded its supportfor the DICOM 3.0 print and storage classes to enable its scannersto make direct connections to DICOM-compatible workstations.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.